Dermatology Times, November 2021 (Vol. 42. No. 11)

Mandell is an attorney and founder of the wealth management firm OJM Group in Cincinnati, Ohio. Braunscheidel is a wealth adviser at OJM Group.

In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explains misinformation surrounding skin and hair cleansing.

Dermatologist urges colleagues to take mindful measures to avoid errors.

In this month's Legal Eagle column, David J. Goldberg, MD, JD, discusses coding and billing in physician practices.

Natural skincare ingredients are always trending, said Patricia K. Farris, MD, hear what she had to say about using these in combination with other regimens.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

Coppertone, David Light, founder and CEO of Valisure, and Christopher Bunick, MD, PhD, share their thoughts on the sunscreen giant’s voluntary recall of 12 lots of its aerosol sunscreen after finding the presence of benzene.

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

In his presentation at Maui Derm NP+PA Fall 2021, Jerry Shapiro, MD, FAAD, shared his treatment protocols for lupus erythematosus, lichen planopilaris, folliculitis decalvans, and dissecting cellulitis.

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

A review of the American Academy of Dermatology guidelines and current treatment improvements for actinic keratosis were discussed during a presentation at Maui Derm NP+PA Fall 2021.

New therapies raise patient expectations for fast efficacy, lower costs, and fewer adverse effects.

Innovations include underserved populations, acne, and advanced applications.